Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Decreases By 64.2%

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 50,300 shares, a decline of 64.2% from the April 30th total of 140,500 shares. Based on an average trading volume of 46,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.2% of the shares of the company are sold short.

Hedge Funds Weigh In On Entera Bio

Hedge funds have recently modified their holdings of the company. HighTower Advisors LLC raised its holdings in Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after acquiring an additional 6,310 shares during the period. Perigon Wealth Management LLC purchased a new position in shares of Entera Bio in the fourth quarter worth $325,000. Northern Trust Corp bought a new position in Entera Bio during the 4th quarter valued at approximately $450,000. Parkman Healthcare Partners LLC lifted its position in shares of Entera Bio by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock worth $747,000 after purchasing an additional 25,900 shares during the period. Finally, Knoll Capital Management LLC boosted its position in shares of Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after purchasing an additional 2,000,000 shares in the last quarter. Institutional investors own 14.11% of the company's stock.

Entera Bio Stock Up 7.0%

Shares of ENTX stock traded up $0.14 on Tuesday, reaching $2.08. The company had a trading volume of 88,925 shares, compared to its average volume of 70,624. The stock has a market capitalization of $94.31 million, a PE ratio of -7.98 and a beta of 1.51. Entera Bio has a one year low of $1.41 and a one year high of $2.79. The business's 50-day moving average is $1.93 and its 200 day moving average is $2.05.

Entera Bio (NASDAQ:ENTX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.04 million for the quarter. On average, sell-side analysts forecast that Entera Bio will post -0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Entera Bio in a research report on Tuesday, March 18th.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.